XRTX - XORTX Therapeutics Inc.
XORTX Therapeutics Inc. , a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $607,106
- Beta
- 0.73
- 52-Week Range
- 1.725-7.05
- CEO
- Allen Warren Davidoff
- Employees
- 2
- IPO Date
- Sep 23, 2021
- Exchange
- NASDAQ
XRTX Options Snapshot
Options pricing data for XRTX is refreshed daily after the close. When listed contracts exist, this page surfaces the latest at-the-money implied volatility, max pain strike, dealer gamma exposure (GEX), and 25-delta skew. Listed contracts and live snapshots appear once the options chain has been published by the exchange for the most recent session.
What This Page Covers
The XRTX overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked XRTX overview questions
- What is XRTX?
- XRTX is the ticker symbol for XORTX Therapeutics Inc., a listed security. XORTX Therapeutics Inc. , a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. Listed on NASDAQ. XRTX is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What are XRTX's key statistics?
- XORTX Therapeutics Inc. (XRTX) carries a market capitalization of $607,106, beta of 0.73 relative to the broader market, 52-week range of 1.725-7.05. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does XRTX belong to?
- XORTX Therapeutics Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare XRTX's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the XRTX data on this page?
- Options snapshots refresh after each trading session; if no snapshot is currently posted for XRTX, it usually reflects low options liquidity or a recently listed name. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).